Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

The Phase 3 ARCHER II trial completes enrollment for vonaprument, targeting vision preservation in dry AMD, with results expected in 2026.

In a press release, Aldeyra Therapeutics, Inc. announced that the European Medicines Agency (EMA) has granted orphan designation for its methotrexate intravitreal injection (ADX-2191). The therapeutic ...

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing tinlarebant's potential to treat geographic atrophy.